Page 6,405«..1020..6,4046,4056,4066,407..6,4106,420..»

Hormone Therapy Reduces Heart Risks, Study Finds

Posted: Published on October 10th, 2012

A new study has found that women who take hormone replacement therapy for 10 years following menopause have significantly reduced risk of heart failure, heart attack, and dying. In addition, those same women are not at any increased risk of cancer, deep vein thrombosis (DVT), or stroke. These findings come just weeks after a different study published in the journal Obstetrics & Gynecology showed that hormone use among postmenopausal women has been declining. Speculation as to the reason for this decline focused on patient and doctor fears based on a 2002 study by the Womens Health Initiative (WHI) that found estrogen/progestin hormone therapy can increase risks of heart attack, stroke, blood clots, and breast cancer. The new study, published today in the journal BMJ, throws into question the results from the WHI research. Researchers from Hvidovre Hospital in Denmark looked at 1006 white, healthy Danish women from ages 45 to 58. After a 10-year randomized trial and six years of follow-up, the study authors concluded that the women treated with long term hormone replacement therapy had significantly reduced risk of mortality, heart failure, or heart attack, without any apparent increase of cancer, DVT, or stroke. ABC news quotes Dr. Louise … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Hormone Therapy Reduces Heart Risks, Study Finds

New research suggests HRT may lower heart risks

Posted: Published on October 10th, 2012

By Amanda Gardner HealthDay Reporter WEDNESDAY, Oct. 10 (HealthDay News) -- New research suggests that women who take hormone replacement therapy in the early stages of menopause may have a reduced risk of heart attack, heart failure or dying. This apparent benefit comes without a heightened risk of cancer or blood clots, the Danish researchers said. These health risks have long been a concern of menopausal women and their doctors when considering hormone therapy. The study, published Oct. 9 in the BMJ, even found evidence of a trend toward a lower risk of breast cancer, although this was not statistically significant, said study author Dr. Louise Lind Schierbeck. However, two doctors not associated with the study said the findings weren't enough to convince them to recommend hormone replacement therapy (HRT) to head off heart problems. But they -- and many doctors -- would prescribe low doses of the therapy for short durations to treat menopausal symptoms such as poor sleep or hot flashes. The new study comes on the heels of two other studies, one finding that HRT was safe for the heart and the other concluding that it did not worsen memory in younger women taking it. Women have … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on New research suggests HRT may lower heart risks

Hormone Replacement Therapy Safe, Study Suggests

Posted: Published on October 10th, 2012

For 10 years, many women going through menopause have shunned hormone replacement therapy after a landmark study suggested a link between HRT and breast cancer. A new study, published online in the medical journal BMJ, suggests a flaw in that initial study: The women in the first report started HRT at an average age of 63. The new study follows women who began HRT at the onset of menopause (the 1,006 women involved in the study were white, healthy, and aged 45-58 years old), and found that not only was there not an increased risk of cancer for the women on HRT, they were less likely to die of heart disease. Half of the women in the study were given HRT for 10 years. After 10 years, 15 women in the HRT group had died and one suffered a heart problem. In the non-HRT group, 26 women had died and seven had had some type of heart problem. The Danish researchers followed the women for another six years, finding that women not on HRT were 40 percent more likely to die or suffer a heart problem than the women on HRT. Rates of breast cancer were the same between the … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy Safe, Study Suggests

Japan stem cell Nobel laureate to get research boost

Posted: Published on October 10th, 2012

Japan's Nobel prize-winning Shinya Yamanaka will likely get up to 30 billion yen ($383 million) for his stem cell research over the next decade, an official said Wednesday. The Japanese science and technology ministry is looking at giving at least 2.7 billion yen of extra money to support Yamanaka's work over the next fiscal year alone, a ministry official said. "The government plans to continue this programme for the following 10 years, while Dr Yamanaka will also receive other subsidies as well," he said on condition of anonymity, adding the grant was already planned before his Nobel prize was announced. The total subsidies likely to be given to the scientist are estimated to be worth up to 30 billion yen over the decade. Yamanaka and Britain's John Gurdon were jointly honoured with the medicine prize for discovering that adult cells can be transformed back to an infant state called stem cells, the key ingredient in the vision of regenerative medicine. The Japanese was singled out for his work in the field of so-called induced pluripotent stem (iPS) cells. So-called "nuclear reprogramming" uses a fully-developed adult cell to create an iPS cell -- a kind of blank slate that has the … Continue reading →

Posted in Stem Cell Research | Comments Off on Japan stem cell Nobel laureate to get research boost

Stem Cell Transplants May Show Promise for Multiple Sclerosis

Posted: Published on October 10th, 2012

Oct. 10, 2012 -- New research suggests that stem cell transplants to treat certain brain and nervous systemdiseases such as multiple sclerosis may be moving closer to reality. One study found that experimental stem cell transplants are safe and possibly effective in children with a rare genetic brain disease. Another study in mice showed that these cells are capable of transforming into, and functioning as, the healthy cell type. The stem cells used in the two studies were developed by study sponsor StemCells, Inc. Both papers appear online in Science Translational Research. The work, while still in its infancy, may have far-reaching implications for the treatment of many more common diseases that affect the brain and nervous system. Researchers out of the University of California, San Francisco (UCSF), looked at the how neural stem cells behaved when transplanted into the brains of four young children with an early-onset, fatal form of Pelizaeus-Merzbacher disease (PMD). PMD is a very rare genetic disorder in which brain cells called oligodendrocytes cant make myelin.Myelin is a fatty substance that insulates the nerve fibers of the brain, spinal cord, and optic nerves (central nervous system), and is essential for transmission of nerve signals so that … Continue reading →

Posted in Stem Cell Research | Comments Off on Stem Cell Transplants May Show Promise for Multiple Sclerosis

FRC Supports Alliance Defending Freedom, Jubilee Campaign Cert Petition to Supreme Court on Stem Cell Funding

Posted: Published on October 10th, 2012

WASHINGTON, Oct. 10, 2012 /PRNewswire-USNewswire/ --Alliance Defending Freedom and the Jubilee Campaign together with Tom Hungar of Gibson, Dunn & Crutcher today filed a petition for certiorari with the U.S. Supreme Court in the case Sherley v. Sebelius, which seeks to end federal funding of human embryonic stem cell research. Of the petition David Prentice, Ph.D., senior fellow for life sciences at the Family Research Council's Center for Human Life and Bioethics, made the following comments: "Even as the Nobel Prize committee honors Japanese scientist Shinya Yamanaka for introducing ethical induced pluripotent stem (iPS) cells to the field of medicine, the Obama administration is fighting to continue wasting taxpayer money on unethical embryonic stem cell research, which relies on the destruction of young human life. A plain reading of federal law would specifically prohibit funding of embryonic stem cell research. After years of wasting taxpayer dollars as well as lives on ethically-tainted experiments, it's time for the federal government to start putting that money into lifesaving and ethical adult stem cell research, the gold standard for patient treatments. Such research is saving thousands of lives now lives like that of Chloe Levine who beat cerebral palsy with the help of … Continue reading →

Comments Off on FRC Supports Alliance Defending Freedom, Jubilee Campaign Cert Petition to Supreme Court on Stem Cell Funding

StemGenex™ on Adult Stem Cell-Based Therapy for Multiple Sclerosis

Posted: Published on October 10th, 2012

LA JOLLA, Calif., Oct. 10, 2012 /PRNewswire/ --New research directions are being explored to find therapies for hard to treat diseases. One exciting new approach is the use of autologous Adult Stem Cells. Multiple Sclerosis (MS) is one of the many notable diseasesadult stem cell therapycould potentially impact. Multiple Sclerosis (MS) is a disorder in which an individual's own immune system attacks the 'myelin sheath'. The myelin sheath serves to protect the nerve cells within the body's central nervous system (CNS). The damage caused by MS may result in many types of symptoms including: (Photo: http://photos.prnewswire.com/prnh/20121010/LA89802-INFO) Currently there is no cure for MS, but MS stem cell therapiesattempt to slow the disease's progression and limit symptoms. Since adult stem cells have the ability to differentiate into many different types of cells, such as those required for proper functioning and protection of nerve cells, the use of adult stem cells for MS therapy could be of substantial value. Adult stem cells can be isolated with relative ease from an individual's own 'adipose' (fat) tissue. As a result, adult stem cell therapy is not subject to the ethical or religious issues troubling embryonic methods. Encouragingly for MS treatment potential, scientific researchers have … Continue reading →

Comments Off on StemGenex™ on Adult Stem Cell-Based Therapy for Multiple Sclerosis

NeoStem Announces New Publication That Supports Positive Results of AMR-001 for Treatment of AMI

Posted: Published on October 10th, 2012

NEW YORK, Oct. 10, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NBS), an emerging leader in the fast growing cell therapy market, announced today that a new article published by the International Scholarly Research Network provides further evidence that AMR-001, NeoStem's lead product candidate through its Amorcyte subsidiary, appears capable of preserving heart muscle function following a large myocardial infarction. Amorcyte demonstrated in its Phase 1 trial that AMR-001 preserved heart muscle function when a therapeutic dose of cells was administered. No patient experienced a deterioration in heart muscle function who received 10 million cells or more whereas 30 to 40 percent of patients not receiving a therapeutic dose did. The new study shows that cardiac muscle function sparing effects are evident even earlier after treatment than previously shown. The article titled "Assessment of myocardial contractile function using global and segmental circumferential strain following intracoronary stem cell infusion after myocardial infarction: MRI Feature Tracking Feasibility Study" by Sabha Bhatti, MD, et al. appears in ISRN Radiology Volume 2013, Article ID 371028 and is published online at http://www.isrn.com/journals/radiology/2013/371028. The publication by Dr. Bhatti and colleagues, including Dr. Andrew Pecora, Chief Medical Officer of NeoStem, supports the finding that AMR-001 preserves heart function. … Continue reading →

Comments Off on NeoStem Announces New Publication That Supports Positive Results of AMR-001 for Treatment of AMI

StemCells, Inc. Announces Simultaneous Publication of Preclinical and Clinical Results of Its Neural Stem Cells for …

Posted: Published on October 10th, 2012

NEWARK, Calif., Oct. 10, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced that two papers reporting clinical and preclinical data demonstrating the therapeutic potential of the Company's proprietary HuCNS-SC(R) cells (purified human neural stem cells) for a range of myelination disorders were published in the Oct. 10 edition of Science Translational Medicine, the peer review journal of the American Association for the Advancement of Science (http://stm.sciencemag.org/). The paper by Gupta, et al. describes the encouraging results of the Company's Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a genetic myelination disorder that afflicts children. In the trial, which was completed in February 2012, four patients were transplanted with the Company's HuCNS-SC cells and all showed preliminary evidence of progressive and durable donor cell-derived myelination. Three of the four patients showed modest gains in their neurological function, which suggests a departure from the natural history of the disease; the fourth patient remained stable. Although clinical benefit cannot be confirmed in a trial without control patients, the small but measureable gains in function at one year may represent signals of a clinical effect to be further investigated in a controlled trial with more patients. The second of the two papers, by … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on StemCells, Inc. Announces Simultaneous Publication of Preclinical and Clinical Results of Its Neural Stem Cells for …

NIH Data Suggests Medistem’s Stem Cell is Unique from Competitor Stem Cells

Posted: Published on October 10th, 2012

SAN DIEGO--(BUSINESS WIRE)-- Medistem Inc. (PINKSHEETS:MEDS) announced today a peer-reviewed publication led by NIH scientists demonstrating that the companys Endometrial Regenerative Cells (ERC) possess a unique genetic signature associated with production of new blood vessels (angiogenesis). The demonstration by an independent group that ERC possess a unique gene signature compared to other stem cells, and that the gene signature is associated with production of new blood vessels, is a strong validation for our programs, said Dr. Thomas Ichim, President and CSO of Medistem. These data support original publications by our group and others that have demonstrated ERC appear to be nature's regenerative powerhouse for production of new blood vessels. According to the publication, the gene encoding aldehyde dehydrogenase, a marker of stem cell potency, was expressed 39.5-fold higher in ERC as compared to bone marrow mesenchymal stem cells (MSC). Additionally, genes associated with production of new blood vessels such as MMP-3, angiopoietin, and PDGF, were expressed 29-fold, 13-fold, and 26-fold higher in ERC as compared to bone marrow MSC, respectively. Currently the majority of scientific effort in development of stem cell therapeutics is associated with bone marrow stem cells. While bone marrow stem cells have many excellent properties, the stem … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on NIH Data Suggests Medistem’s Stem Cell is Unique from Competitor Stem Cells

Page 6,405«..1020..6,4046,4056,4066,407..6,4106,420..»